The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Treatment with PD-1 inhibitors in NSCLC beyond disease progression: Impact on symptoms and cost.
 
Mor Tal Moskovitz
Honoraria - AstraZeneca; Boehringer Ingelheim; Roche/Genentech
Travel, Accommodations, Expenses - Boehringer Ingelheim; Bristol-Myers Squibb
 
Priscilla M Matthews
No Relationships to Disclose
 
Alexandra M Pavel
No Relationships to Disclose
 
Wei Xu
No Relationships to Disclose
 
Penelope Ann Bradbury
No Relationships to Disclose
 
Geoffrey Liu
Honoraria - novartis; pfizer
Consulting or Advisory Role - AstraZeneca/MedImmune; novartis; pfizer; Roche Canada; takeda
Research Funding - roche (Inst)
 
Frances A. Shepherd
Stock and Other Ownership Interests - AstraZeneca; Lilly
Honoraria - AstraZeneca; Bristol-Myers Squibb; Lilly; Merck Serono; Merck Sharp & Dohme; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Lilly; Merck Serono
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Ipsen (Inst); Lilly (Inst); Merrimack (Inst); Pfizer (Inst); Roche Canada (Inst)
 
Natasha B. Leighl
Research Funding - Novartis (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Merck Sharp & Dohme; Pfizer